Bioventus (Bioventus) Price-to-Operating-Cash-Flow : 16.24 (As of Apr. 28, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bioventus Price-to-Operating-Cash-Flow?

As of today (2024-04-28), Bioventus's share price is $3.98. Bioventus's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.25. Hence, Bioventus's Price-to-Operating-Cash-Flow Ratio for today is 16.24.

The historical rank and industry rank for Bioventus's Price-to-Operating-Cash-Flow or its related term are showing as below:

BVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.03 Med: 18.28 Max: 52.49
Current: 16.24

During the past 9 years, Bioventus's highest Price-to-Operating-Cash-Flow Ratio was 52.49. The lowest was 6.03. And the median was 18.28.

BVS's Price-to-Operating-Cash-Flow is ranked better than
61.73% of 439 companies
in the Medical Devices & Instruments industry
Industry Median: 21 vs BVS: 16.24

Bioventus's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $0.16. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.25.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -49.50% per year.

During the past 9 years, Bioventus's highest 3-Year average Operating Cash Flow per Share Growth Rate was 154.90% per year. The lowest was -49.50% per year. And the median was 39.10% per year.

Bioventus Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Bioventus's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventus Price-to-Operating-Cash-Flow Chart

Bioventus Annual Data

Trend

Dec13

Dec14

Dec15

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

37.54

21.51

Bioventus Quarterly Data
	Mar16	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	6.60	10.07	19.88	21.51

Competitive Comparison of Bioventus's Price-to-Operating-Cash-Flow

For the Medical Devices subindustry, Bioventus's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioventus's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Bioventus's Price-to-Operating-Cash-Flow falls into.

Bioventus Price-to-Operating-Cash-Flow Calculation

Bioventus's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	3.98	/	0.245
	=	16.24

Bioventus's Share Price of today is $3.98.
Bioventus's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Bioventus Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Bioventus's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioventus (Bioventus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioventus Inc (NAS:BVS) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703

Website

https://www.bioventus.com

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in U.S and International markets.

Executives

Bihl Anthony P Iii	director, officer: Interim CEO	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
John A. Bartholdson	director, 10 percent owner	C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Juniper Investment Company, Llc	10 percent owner	555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315
Katrina J Church	officer: SVP & Chief Compliance Officer	3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303
Alexis P Michas	10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Juniper Targeted Opportunities, Lp	10 percent owner	555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022
Juniper Targeted Opportunity Fund, L.p.	10 percent owner	555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022
William A Hawkins	director	MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Mark Leonard Singleton	officer: SEE REMARKS	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Anthony D'adamio	officer: SVP & General Counsel	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Kenneth Michael Reali	director, officer: Chief Executive Officer	5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613
John Nosenzo	officer: Chief Commercial Officer	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Alessandra Pavesio	officer: SVP & Chief Science Officer	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gregory O. Anglum	officer: SVP and CFO	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Michelle Mcmurry-heath	director	C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703